实用医学杂志 ›› 2023, Vol. 39 ›› Issue (6): 730-737.doi: 10.3969/j.issn.1006⁃5725.2023.06.013

• 临床研究 • 上一篇    下一篇

SLC5A12在食管鳞癌中表达的临床意义及其对食管鳞癌细胞恶性表型的影响 

丁姝1 韩卓莹1 张博为1 于伟勇2 罗超1,3    

  1. 南京医科大学附属淮安第一医院 1 中心实验室,2 肿瘤科,3 食管癌生物样本库(江苏淮安223300)

  • 出版日期:2023-03-25 发布日期:2023-03-25
  • 通讯作者: 罗超 E⁃mail:hayylch@njmu.edu.cn;于伟勇 E⁃mail:ywy_ema@126.com
  • 基金资助:
    淮安市创新能力建设⁃淮安市免疫学重点实验室(编号:HAP202002);江苏省双创博士(编号:202031099);南京医科大学苏北临床研究院转化医学创新人才项目(编号:YZHR201901)

Clinical significance of SLC5A12 expression in esophageal squamous cell carcinoma and its effect on malig⁃ nant phenotype of esophageal squamous cell carcinoma

DING Shu*,HAN Zhuoying,ZHANG Bowei,YU Weiyong,LUO Chao.   

  1. Department of Central Laboratory,the Affiliated Huaian No.1 People′s Hospital,Nanjing Medical University,Huai′an 223300,China
  • Online:2023-03-25 Published:2023-03-25
  • Contact: LUO Chao E⁃mail:hayylch@njmu.edu.cn;YU Weiyong E⁃mail:ywy_ema@126.com

摘要:

目的 通过蛋白质谱测序筛选与食管鳞癌(esophageal squamous cell carcinoma,ESCC)预后 相关基因SLC5A12并探讨其对ESCC 细胞恶性表型的影响。方法 蛋白质谱测序筛选在ESCC 中差异表达 的蛋白质,公共数据库筛选差异蛋白中与 ESCC 预后相关的基因 SLC5A12 并分析数据库中 ESCC 患者 SLC5A12表达与预后的关系。对生物样本库中随访信息完善的117例ESCC患者配对的肿瘤及正常组织制作 的组织芯片进行免疫组织化学染色,分析 SLC5A12 ESCC 中的表达及其与患者临床病理和预后的关系。 小干扰RNA敲减ESCC细胞中SLC5A12表达,检测细胞的增殖、侵袭及迁移能力。结果 ESCC中共有235 蛋白质表达上调,362个蛋白质表达下调,其中SLC5A12表达显著高于正常组织(log2 fold = 1.33,P = 0.000 4)。 TCGA ESCC 患者 SLC5A12 表达显著高于正常组织及食管腺癌,且 N 分期及 SLC5A12 表达是患者生存的 风险因素,SLC5A12 表达与 ESCC 患者总生存[HR = 2.74,95%CI:1.27 ~ 5.94,P = 0.012]及疾病特异性生 存[HR = 3.14,95%CI:1.24 ~ 7.95,P = 0.02]显著相关。组织芯片免疫组织化学染色结果证实,SLC5A12 ESCC中表达显著高于正常组织,且在淋巴结转移患者中显著高于未转移者。SLC5A12表达水平与ESCC 者总生存期(P < 0.000 1)、病理分期(P < 0.001)及淋巴结转移(P < 0.001)显著相关。敲减SLC5A12表达后, ESCC 细胞的增殖、侵袭及迁移能力均显著降低。结论 SLC5A12 ESCC 中表达显著高于正常组织且与 患者的预后、病理分期及淋巴结转移显著相关,SLC5A12能够促进ESCC细胞的恶性表型进展。

关键词:

SLC5A12, 食管鳞癌, 预后, 恶性表型 ,

Abstract:

Objective To screen the prognosis ⁃ related gene SLC5A12 of esophageal squamous cell carcinoma by protein profiling and explore its effect on the malignant phenotype of ESCC cells. Methods Protein profiling was performed to screen for differentially expressed proteins in ESCC,and public databases were used to screen for SLC5A12,a gene associated with prognosis in ESCC,and to analyze the relationship between SLC5A12 expression and prognosis in ESCC patients in the database. Immunohistochemical staining of tissue microarrays made from paired tumor and normal tissues of 117 ESCC patients with perfect follow⁃up information in the biospeci⁃ men database was performed to analyze the expression of SLC5A12 in ESCC and its relationship with the clinicopa⁃ thology and prognosis of patients. Small interfering RNA knocked down the expression of SLC5A12 in ESCC cells, and the proliferation,invasion and migration ability of the cells were detected. Results A total of 235 protein expressions were upregulated and 362 protein expressions were downregulated in ESCC,in which SLC5A12 expres⁃ sion was significantly higher than that in normal tissues(log2 fold = 1.33,= 0.0004). SLC5A12 expression in ESCC patients in TCGA was significantly higher than that in normal tissues and esophageal adenocarcinoma,and N stage and SLC5A12 expression were risk factors for patient survival factors,and SLC5A12 expression was signifi⁃ cantly associated with overall survival[HR = 2.74,95%CI:1.27 ~ 5.94,= 0.012]and disease⁃specific survival [HR = 3.14,95%CI:1.24 ~ 7.95,= 0.02]in ESCC patients. Immunohistochemical staining of tissue microarraysconfirmed that SLC5A12 expression was significantly higher in ESCC than in normal tissues and significantly higher in patients with lymph node metastases than in those without metastases. SLC5A12 expression levels were signifi⁃ cantly correlated with overall survival(< 0.000 1),pathological stage(< 0.001)and lymph node metastases (< 0.001)in ESCC patients. The proliferation,invasion and migration ability of ESCC cells were significantly reduced after knockdown of SLC5A12 expression. Conclusions SLC5A12 expression in ESCC was significantly higher than that in normal tissues and significantly correlated with the prognosis,pathological stage and lymph node metastasis of patients,and SLC5A12 could promote the malignant phenotype progression of ESCC cells.

Key words:

SLC5A12, esophageal squamous cell carcinoma, prognosis, malignant phenotype